Asia-Pacific Monoclonal Antibodies Market by Source (Murine, Chimeric, Humanized, Human) by Indication (Cancer, Autoimmune diseases, infectious diseases, Cardiovascular diseases, CNS disorders, others) by End-User (Hospitals/Clinics, Research Institute, Diagnostic Laboratories) by Application (Medical, Experimental) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021

Asia-Pacific Monoclonal Antibodies Market by Source (Murine, Chimeric, Humanized, Human) by Indication (Cancer, Autoimmune diseases, infectious diseases, Cardiovascular diseases, CNS disorders, others) by End-User (Hospitals/Clinics, Research Institute, Diagnostic Laboratories) by Application (Medical, Experimental) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021

ID: 1187 | Pages: 137 | November 2016 | Region: Asia-Pacific


Asia-Pacific Monoclonal Antibodies Market is estimated to be $10397.7073 million in 2016 and expected to grow at a Compound Annual Growth Rate of 4.52%, to reach $12969.84 million by 2021. mAb`s are antibodies that are made by identical immune cells that are all clones of a unique parent cell, in distinction to polyclonal antibodies, which are made by numerous different immune cells. Monoclonal Antibodies market in Asia-Pacific region is gaining momentum due to increasing awareness among patients and physicians about application of mAb`s in various diseases.

Asia-Pacific Monoclonal Antibodies market is driven by factors such as patent expiries of key biological drugs, aging population, increasing disposable income, and supporting legislations. The development of new molecules is also expected to play a key role in the future of the market. Rising government initiatives supporting the use of mAbs for research and treatment purposes along with an upsurge in R&D activities for the development of cost-effective therapeutic mAbs are also driving the market for Monoclonal Antibodies market. However, amount of money and time required for the identification and development of potential molecules is huge and is a major factor restraining the market growth.

Asia-Pacific market for Monoclonal Antibodies is broadly segmented into Source, Indication, End User and Application. Based on source, the market is segmented into Murine, Chimeric, Humanized and Human. Human mAb`s accounted for the largest share of the market with a share of approximately XX%. On the basis of indication, the Asia-Pacific mAb`s market is categorized into cancer, Auto immune diseases, Infectious diseases, Cardiovascular diseases, CNS disorders and others. Cancer Vaccines are further sub segmented into Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer and Others. By end user, the market is segmented into Hospitals/Clinics, Research Institute and Diagnostic Laboratories. Hospitals is the largest end user segment accounting for a share of approximately XX% while diagnostic laboratories are estimated to be the fastest growing due to its increasing applications. On the basis of application Asia-Pacific monoclonal antibodies market is segmented into medical and experimental. By experimental application the market is further sub segmented into Western Blot, ELISA, Radioimmune Assays, Immunofluorescence and others.

Asia-Pacific is the fastest growing region for Monoclonal antibodies market owing to huge population and increasing disposable income of people. Geographically Asia-Pacific monoclonal antibodies market is segmented into China, India, Japan, South Korea and Australia. Within Asia-Pacific, China is the largest market while India is estimated to be the fastest growing.

Some of the major companies dominating the market, by their products include GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Eli Lilly and Company (U.S.), Innovent Biologics (China), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland) and Shanghai Junshi Bioscience Co.,Ltd. (China).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Indication                              

                                5.2.1 Cancer      

                                                5.2.1.1 Blood Cancer

                                                5.2.1.2 Breast Cancer

                                                5.2.1.3 Colorectal Cancer

                                                5.2.1.4 Lung Cancer

                                                5.2.1.5 Pancreatic Cancer

                                                5.2.1.6 Others

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Asia-Pacific                 

                                6.1.1 Introduction           

                                6.1.2 China         

                                6.1.3 India          

                                6.1.4 Japan        

                                6.1.5 South Korea           

                                6.1.6 Australia  

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 Innovent Biologics (China)                   

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.8 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.9 Shanghai Junshi Bioscience Co.,Ltd. (China)                  

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

TitlePriceAdd To Cart
  1. Asia-Pacific Monoclonal Antibodies Market By Murine, From 2016-2021 ( USD Million )
  2. Asia-Pacific Chimeric Market By Region, From 2016-2021 ( USD Million )
  3. Asia-Pacific Humanized Market By Region, From 2016-2021 ( USD Million )
  4. Asia-Pacific Human Market By Region, From 2016-2021 ( USD Million )
  5. Asia-Pacific Monoclonal Antibodies Market By Cancer, From 2016-2021 ( USD Million )
  6. Asia-Pacific Autoimmune Diseases Market By Region, From 2016-2021 ( USD Million )
  7. Asia-Pacific Infectious Diseases Market By Region, From 2016-2021 ( USD Million )
  8. Asia-Pacific Cardiovascular Diseases Market By Region, From 2016-2021 ( USD Million )
  9. Asia-Pacific CNS Disorders Market By Region, From 2016-2021 ( USD Million )
  10. Asia-Pacific Others (Inflammatory, Microbial Diseases, & Other) Market By Region, From 2016-2021 ( USD Million )
  11. Asia-Pacific Monoclonal Antibodies Market By Hospitals/Clinics, From 2016-2021 ( USD Million )
  12. Asia-Pacific Research Institute Market By Region, From 2016-2021 ( USD Million )
  13. Asia-Pacific Diagnostic Laboratories Market By Region, From 2016-2021 ( USD Million )
  14. Asia-Pacific Monoclonal Antibodies Market By Medical, From 2016-2021 ( USD Million )
  15. Asia-Pacific Experimental Market By Region, From 2016-2021 ( USD Million )
  16. Japan Monoclonal Antibodies Market By Murine, From 2016-2021 ( USD Million )
  17. Japan Monoclonal Antibodies Market By Cancer, From 2016-2021 ( USD Million )
  18. Japan Monoclonal Antibodies Market By Hospitals/Clinics, From 2016-2021 ( USD Million )
  19. Japan Monoclonal Antibodies Market By Medical, From 2016-2021 ( USD Million )
  20. China Monoclonal Antibodies Market By Murine, From 2016-2021 ( USD Million )
  21. China Monoclonal Antibodies Market By Cancer, From 2016-2021 ( USD Million )
  22. China Monoclonal Antibodies Market By Hospitals/Clinics, From 2016-2021 ( USD Million )
  23. China Monoclonal Antibodies Market By Medical, From 2016-2021 ( USD Million )
  24. India Monoclonal Antibodies Market By Murine, From 2016-2021 ( USD Million )
  25. India Monoclonal Antibodies Market By Cancer, From 2016-2021 ( USD Million )
  26. India Monoclonal Antibodies Market By Hospitals/Clinics, From 2016-2021 ( USD Million )
  27. India Monoclonal Antibodies Market By Medical, From 2016-2021 ( USD Million )
  28. South Korea Monoclonal Antibodies Market By Murine, From 2016-2021 ( USD Million )
  29. South Korea Monoclonal Antibodies Market By Cancer, From 2016-2021 ( USD Million )
  30. South Korea Monoclonal Antibodies Market By Hospitals/Clinics, From 2016-2021 ( USD Million )
  31. South Korea Monoclonal Antibodies Market By Medical, From 2016-2021 ( USD Million )
  32. Australia Monoclonal Antibodies Market By Murine, From 2016-2021 ( USD Million )
  33. Australia Monoclonal Antibodies Market By Cancer, From 2016-2021 ( USD Million )
  34. Australia Monoclonal Antibodies Market By Hospitals/Clinics, From 2016-2021 ( USD Million )
  35. Australia Monoclonal Antibodies Market By Medical, From 2016-2021 ( USD Million )
  36. Asia-Pacific Monoclonal Antibodies Market By Blood Cancer, From 2016-2021 ( USD Million )
  37. Asia-Pacific Breast Cancer Market By Region, From 2016-2021 ( USD Million )
  38. Asia-Pacific Colorectal Cancer Market By Region, From 2016-2021 ( USD Million )
  39. Asia-Pacific Lung Cancer Market By Region, From 2016-2021 ( USD Million )
  40. Asia-Pacific Pancreatic Cancer Market By Region, From 2016-2021 ( USD Million )
  41. Asia-Pacific Others Market By Region, From 2016-2021 ( USD Million )
  42. Japan Monoclonal Antibodies Market By Blood Cancer, From 2016-2021 ( USD Million )
  43. China Monoclonal Antibodies Market By Blood Cancer, From 2016-2021 ( USD Million )
  44. India Monoclonal Antibodies Market By Blood Cancer, From 2016-2021 ( USD Million )
  45. Souh Korea Monoclonal Antibodies Market By Blood Cancer, From 2016-2021 ( USD Million )
  46. Asia-Pacific Monoclonal Antibodies Market By Western Blot, From 2016-2021 ( USD Million )
  47. Asia-Pacific ELISA Market By Region, From 2016-2021 ( USD Million )
  48. Asia-Pacific Radioimmune Assays Market By Region, From 2016-2021 ( USD Million )
  49. Asia-Pacific Immunofluorescence Market By Region, From 2016-2021 ( USD Million )
  50. Asia-Pacific Others Market By Region, From 2016-2021 ( USD Million )
  51. Japan Monoclonal Antibodies Market By Western Blot, From 2016-2021 ( USD Million )
  52. China Monoclonal Antibodies Market By Western Blot, From 2016-2021 ( USD Million )
  53. India Monoclonal Antibodies Market By Western Blot, From 2016-2021 ( USD Million )
  54. Souh Korea Monoclonal Antibodies Market By Western Blot, From 2016-2021 ( USD Million )

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
502, kakatiya's empire,
Jubilee Gardens,
Hyderabad, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.